Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials

Masayoshi Harigai, Tsutomu Takeuchi, Josef S. Smolen, Kevin L. Winthrop, Atsushi Nishikawa, Terence P. Rooney, Chadi G. Saifan, Maher Issa, Yoshitaka Isaka, Naotsugu Akashi, Taeko Ishii, Yoshiya Tanaka

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Fingerprint

Dive into the research topics of 'Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials'. Together they form a unique fingerprint.

Medicine & Life Sciences